202 related articles for article (PubMed ID: 37301953)
1. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.
Jakubowski A; Fowler S; Fox AD
Addict Sci Clin Pract; 2023 Jun; 18(1):40. PubMed ID: 37301953
[TBL] [Abstract][Full Text] [Related]
2. "We'll be able to take care of ourselves" - A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs.
Frost T; Deutsch S; Brown S; Lemien E; Cunningham CO; Fox AD
Subst Abus; 2021; 42(4):983-989. PubMed ID: 33759722
[No Abstract] [Full Text] [Related]
3. Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation.
Jakubowski A; Rath C; Harocopos A; Wright M; Welch A; Kattan J; Navos Behrends C; Lopez-Castro T; Fox AD
Harm Reduct J; 2022 Jul; 19(1):75. PubMed ID: 35818071
[TBL] [Abstract][Full Text] [Related]
4. Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale.
Perez-Correa A; Abbas B; Riback L; Ghiroli M; Norton B; Murphy S; Jakubowski A; Hayes BT; Cunningham CO; Fox AD
Contemp Clin Trials; 2022 Mar; 114():106674. PubMed ID: 34990854
[TBL] [Abstract][Full Text] [Related]
5. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
[TBL] [Abstract][Full Text] [Related]
6. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
[TBL] [Abstract][Full Text] [Related]
7. Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial.
Watson DP; Swartz JA; Robison-Taylor L; Mackesy-Amiti ME; Erwin K; Gastala N; Jimenez AD; Staton MD; Messmer S
BMC Public Health; 2021 Mar; 21(1):630. PubMed ID: 33789642
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
9. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
[TBL] [Abstract][Full Text] [Related]
10. Gender disparities in opioid treatment progress in methadone versus counseling.
Guerrero E; Amaro H; Kong Y; Khachikian T; Marsh JC
Subst Abuse Treat Prev Policy; 2021 Jun; 16(1):52. PubMed ID: 34162420
[TBL] [Abstract][Full Text] [Related]
11. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.
Corneli A; Perry B; Des Marais A; Choi Y; Chen H; Lilly R; Ayers D; Bennett J; Kestner L; Meade CS; Sachdeva N; McKellar MS
Harm Reduct J; 2022 Dec; 19(1):132. PubMed ID: 36463214
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
[No Abstract] [Full Text] [Related]
13. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
Randall-Kosich O; Andraka-Christou B; Totaram R; Alamo J; Nadig M
J Addict Med; 2020; 14(4):e44-e52. PubMed ID: 31651562
[TBL] [Abstract][Full Text] [Related]
14. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
[TBL] [Abstract][Full Text] [Related]
15. Scoping review of interventions to link individuals to substance use services at discharge from jail.
Grella CE; Ostlie E; Watson DP; Scott CK; Carnevale J; Dennis ML
J Subst Abuse Treat; 2022 Jul; 138():108718. PubMed ID: 35012792
[TBL] [Abstract][Full Text] [Related]
16. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
17. The estimated impact of state-level support for expanded delivery of substance use disorder treatment during the COVID-19 pandemic.
Nesoff ED; Marziali ME; Martins SS
Addiction; 2022 Jun; 117(6):1781-1786. PubMed ID: 34873783
[TBL] [Abstract][Full Text] [Related]
18. Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.
Andraka-Christou B; Saloner B; Gordon AJ; Totaram R; Randall-Kosich O; Golan M; Stein BD
Am J Drug Alcohol Abuse; 2022 Jul; 48(4):492-503. PubMed ID: 35772010
[No Abstract] [Full Text] [Related]
19. Substance use disorder bridge clinics: models, evidence, and future directions.
Taylor JL; Wakeman SE; Walley AY; Kehoe LG
Addict Sci Clin Pract; 2023 Apr; 18(1):23. PubMed ID: 37055851
[TBL] [Abstract][Full Text] [Related]
20. Posttraumatic stress disorder in people who use drugs: syringe services program utilization, treatment need, and preferences for onsite mental health care.
López-Castro T; Sohler N; Riback L; Bravo G; Ohlendorf E; Ghiroli M; Fox AD
Harm Reduct J; 2024 Jun; 21(1):108. PubMed ID: 38824597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
